Renalytix (Reg S) (RENX)

Sector:

Health Care

Index:

FTSE AIM All-Share

10.75p
   
  • Change Today:
      0.79p
  • 52 Week High: 50.40
  • 52 Week Low: 6.75
  • Currency: UK Pounds
  • Shares Issued: 189.93m
  • Volume: 1,207,007
  • Market Cap: £20.42m
  • RiskGrade: 348
  • Beta: 1.27

Renalytix inks partnership with Singing River Health System

By Josh White

Date: Monday 10 Jan 2022

LONDON (ShareCast) - (Sharecast News) - Renalytix announced a partnership with Singing River Health System to deploy 'KidneyIntelX' informed care management on Monday, to improve kidney health in individuals with type-2 diabetes and early-stage chronic kidney disease.
The AIM-traded firm said its KidneyIntelX platform would enable Singing River's primary and specialty care providers to easily identify and understand a person's kidney health risks, implement medication and nutrition management, and provide educational intervention on a timely basis.

It described Singing River as a "mission-driven" healthcare provider with locations across the Mississippi Gulf Coast - a region with one of the highest rates of diabetes in the United States.

The partnership between Singing River and Renalytix would focus on improving health outcomes and reducing healthcare costs in the high-risk population, by driving early detection and providing informed care in seeking to delay disease progression and prevent unnecessary dialysis starts.

About 25% of Mississippi's three million residents were currently enrolled in Medicaid health benefits, Renalytix noted, with reports estimating the state's direct and indirect costs of diabetes and its associated conditions such as chronic kidney disease as high as $3.4bn annually.

Recent data also showed that Mississippi continued to be one of the worst states at providing better outcomes and access to healthcare in the Black and Latinx communities, who were already at an increased risk of developing diabetes and chronic kidney disease.

"From the beginning, Renalytix has been committed to taking immediate action to mitigate racial and economic disparities in kidney disease care," said company president Tom McLain.

"In addition to our new partnership with Singing River, we have secured provider agreements with 27 state Medicaid programs.

"We believe that precision medicine approaches, including KidneyIntelX, will ensure that the right treatment gets to the right patients, regardless of population type, economic status or health insurance coverage."

Singing River Health System was Renalytix's first partner along the Gulf Coast.

The company said the health system expansion of KidneyIntelX was also supported by the recent launch within the General Services Administration, which granted a 10-year government-wide contract for KidneyIntelX, which was also covered under numerous commercial insurance programmes.

At 1203 GMT, shares in Renalytix were up 2.2% in London, at 557p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

RENX Market Data

Currency UK Pounds
Share Price 10.75p
Change Today 0.79p
% Change 7.93 %
52 Week High 50.40
52 Week Low 6.75
Volume 1,207,007
Shares Issued 189.93m
Market Cap £20.42m
Beta 1.27
RiskGrade 348

RENX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
16.43% above the market average16.43% above the market average16.43% above the market average16.43% above the market average16.43% above the market average
65.71% above the sector average65.71% above the sector average65.71% above the sector average65.71% above the sector average65.71% above the sector average
Price Trend
76.86% below the market average76.86% below the market average76.86% below the market average76.86% below the market average76.86% below the market average
67.57% below the sector average67.57% below the sector average67.57% below the sector average67.57% below the sector average67.57% below the sector average
Income Not Available
Growth
34.7% below the market average34.7% below the market average34.7% below the market average34.7% below the market average34.7% below the market average
50% below the sector average50% below the sector average50% below the sector average50% below the sector average50% below the sector average

RENX Dividends

No dividends found

Trades for 24-Dec-2024

Time Volume / Share Price
11:37 250,000 @ 10.50p
11:24 200,000 @ 10.50p
12:15 1,822 @ 10.98p
12:06 4,625 @ 10.81p
11:53 46,253 @ 10.81p

RENX Key Personnel

CEO James Renwick McCullough

Top of Page